ecco
Interviews and expert commentary tagged “ecco” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Oral Capecitabine: As Good As Fluorouracil Second Line for Metastatic Colorectal Cancer
David Cunningham REFERENCE: Abstract 3012, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 DAVID CUNNINGHAM, Royal Marsden Hospital, London The oral agent capeticabine
Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone
Cora Sternberg REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 CORA STERNBERG, San Camillo and Forlanini Hospital, Rome Satraplatin could pro
Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Jean-Yves Douillard Gordon McVie REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer Conference, Barcelona, 23 Р27 September 2007 JEAN-YVES DOUILLARD, Centre Ren̩ Gauducheau, N
Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer
Nicholas James Gordon McVie REFERENCE: Abstract: 3LB (Presidential Session), ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 NICHOLAS JAMES, Birmingham University COMM
Neoadjuvant Trastuzumab: Marked Benefit in HER2-Positive Inflammatory Breast Cancer
Jose Baselga Gordon McVie REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona CO
Intraperitoneal Catumaxomab Prolongs Survival in Patients With Malignant Ascites from Ovarian Cancer
Markus Heiss REFERENCE: ABSTRACT 5001, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 MARKUS HEISS, Klinikum Cologne, Merheim For patients with malignant ascites as a
Breast Cancer: Further Support for Trastuzumab from Combined Analysis
Edward Romond Edward Romond, University of Kentucky, Lexington More data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding